In the same study, matched paracancerous tissue from patients pre- and post-enzalutamide treatment showed no significant increase in ST3GAL1 levels following treatment (Supplementary Fig. 2f), suggesting that the observed increase in ST3GAL1 is specific to prostate tumours. The gene discussed is ST3GAL1; the disease is prostate neoplasm.